Blackhawk Plastic Surgery and other practices report a surge in post-weight-loss body contouring procedures, directly driven by GLP-1 agonist adoption (semaglutide, tirzepatide). Patients achieving 30–50+ pound weight loss via pharmaceutical intervention are seeking surgical and non-invasive skin tightening, liposuction, and RF/ultrasound treatments to address loose skin and contour irregularities.
Market
GLP-1 Weight-Loss Boom Drives Post-Bariatric Body Contouring Surge — New Patient Pipeline for Medspas
Ozempic, Mounjaro adoption fuels demand for skin tightening and liposuction; practices report increased surgical referrals.
GLP-1 weight-loss boom drives surge in post-bariatric body contouring and skin tightening procedures.
For medspas, this represents a significant new patient acquisition channel: practices offering RF microneedling, monopolar RF, and ultrasound skin tightening can position these as bridge or maintenance treatments pre- or post-surgical body contouring. The GLP-1 boom is creating a multi-year tailwind for energy-device utilization and procedure volume, particularly in markets with high obesity rates and strong GLP-1 adoption. Practices should evaluate RF and ultrasound capital allocation with this patient pipeline in mind.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.